Navigation Links
12th U.S. Patent Issued To Dyadic International
Date:11/19/2012

JUPITER, Fla., Nov. 19, 2012 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,304,212 entitled "Methods and compositions for degradation of lignocellulosic material" by the United States Patent and Trademark Office ("USPTO").

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

The inventions embodied by this patent relate to methods and compositions for using enzyme mixtures to convert plant biomass into fermentable sugars for the production of useful products. The inventions also relate to novel combinations of enzymes including those that provide a synergistic release of sugars from plant biomass.

Dyadic's President and CEO, Mark Emalfarb, stated, "In developing and selling industrial enzymes, our customers and partners not only benefit from Dyadic's patented C1 platform technology but also from Dyadic's fungal strains and technologies based on the Trichoderma fungal organism. Dyadic uses these strains to produce specialty enzymes that can be used for a variety of applications in such fields as animal health and nutrition, biofuels and bio-based chemicals. As with our growing portfolio of patents covering the C1 technology, this patent will provide Dyadic, its customers and licensees with additional protection for our Trichoderma-based enzyme mixtures."

The patent also specifically describes methods of increasing the yield of fermentable sugars from fermentation of Distillers Dried Grains (DDGs) using enzyme mixtures comprising glucoamylase, beta-glucosidase and alpha-arabinofuranosidase. DDGs are obtained after the fermentation of the starch der
'/>"/>

SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Enbrel® (etanercept) Patent Issued
2. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
3. Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
6. Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications
7. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
8. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
9. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
10. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
11. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Asia ... through 2023 as the aging population, increasing adoption of ... all spur procedure volumes. Growth will be particularly rapid ... and India , where rising ... a larger proportion of the population. Other ...
(Date:12/17/2014)... 2014 The Activated Carbon Manufacturing ... is why IBISWorld updated its original industry research report. ... from an intensified focus on environmental policy. Over the ... standards for power plants and a range of other ... Industry Analyst Sarah Kahn, “a range of downstream industrial ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... April 3, 2012 Hamamatsu Corporation announces that ... through third-party dealers, will now be available through ... company is responsible for the sales, marketing, and ... line for new customers throughout North America. Existing ...
... TORONTO, April 3, 2012  Generex Biotechnology Corporation (OTCBB: GNBT.OB) ... (AACR) chose to spotlight a presentation on data from ... to prevent relapse in patients who have had breast ... conference.  The annual AACR meeting is one of the ...
... Biopharmaceutical Services, Inc. a full-service biopharmaceutical contract development and ... Utterback to the company,s Board of Directors. ... is an invaluable addition to our board, and we ... knowledge," said Michael A. Griffith, Chief Executive Officer. ...
Cached Biology Technology:Hamamatsu Corporation Announces Exclusive Distribution of Its NanoZoomer Whole-Slide Scanners 2Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 2Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 3Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 4Laureate Biopharma Names James D. Utterback to Board of Directors 2
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... a fast-food restaurant reduces the calories in a children,s ... size of French fries? Would children compensate by choosing ... Cornell University, Dr. Brian Wansink and Dr. Andrew Hanks, ... answer that question. Prior to 2012, the Happy ...
... high-resolution video, scientists have discovered important new information ... behavior that determines individual dispersal and ultimately, survival. ... (WHOI) and Stony Brook University grew Atlantic slipper ... grain of sand, and recorded microscopic video of ...
... (NSF) recently awarded more than $12.5 million in ... each targeting important societal challenges that can be ... to four-year grants will allow researchers to plan, ... technologies and tools to increase sustainability. ...
Cached Biology News:Healthier Happy Meals 2New study reveals the biomechanics of how marine snail larvae swim 2NSF supports collaborative cyber-enabled research to advance sustainability 2NSF supports collaborative cyber-enabled research to advance sustainability 3
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... Perhaps sheer in-house demand is causing shortages ... your precious antibody. This can cause unwanted ... • Receive royalties for your hard work ... let us build it up and market ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
...
Biology Products: